vyepti
h. lundbeck a/s - eptinezumab - poruchy migrény - analgetiká - vyepti is indicated for the prophylaxis of migraine in adults who have at least 4 migraine days per month.
hemlibra
roche registration limited - emicizumab - hemofília a - antihemoragiká - hemlibra is indicated for routine prophylaxis of bleeding episodes in patients with haemophilia a (congenital factor viii deficiency):with factor viii inhibitorswithout factor viii inhibitors who have:severe disease (fviii < 1%)moderate disease (fviii ≥ 1% and ≤ 5%) with severe bleeding phenotype. hemlibra môžu byť použité vo všetkých vekových skupinách.
raylumis
pfizer europe ma eeig - tanezumab - osteoarthritis; pain - analgetiká - treatment of moderate to severe chronic pain associated with osteoarthritis (oa) of the hip or knee in adult patients for whom treatment with non-steroidal anti-inflammatory drugs (nsaids) and/or any opioid is ineffective, not tolerated or inappropriate.
feiba 50 u/ml
baxalta innovations gmbh, rakúsko - faktor viii - inhibítor bypassovej aktivity - 16 - anticoagulantia (fibrinolytica, antifibrinol.)
feiba 25 u/ml
baxalta innovations gmbh, rakúsko - faktor viii - inhibítor bypassovej aktivity - 16 - anticoagulantia (fibrinolytica, antifibrinol.)
feiba 50 u/ml prášok a rozpúšťadlo na infúzny roztok
baxalta innovations gmbh, rakúsko - faktor viii - inhibítor bypassovej aktivity - 16 - anticoagulantia (fibrinolytica, antifibrinol.)
feiba 25 u/ml prášok a rozpúšťadlo na infúzny roztok
baxalta innovations gmbh, rakúsko - faktor viii - inhibítor bypassovej aktivity - 16 - anticoagulantia (fibrinolytica, antifibrinol.)
roctavian
biomarin international limited - valoctocogene roxaparvovec - antihemoragiká - treatment of severe haemophilia a (congenital factor viii deficiency) in adult patients without a history of factor viii inhibitors and without detectable antibodies to adeno-associated virus serotype 5 (aav5).